Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing hepatitis C.

Bruce R Bacon1

  • 1Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, Missouri, USA.

The American Journal of Managed Care
|April 16, 2004
PubMed
Summary
This summary is machine-generated.

New drug regimens for hepatitis C virus (HCV) offer effective treatment. Peginterferon alfa and ribavirin combination therapy shows sustained virologic response in over half of patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerating Care Through ECHO: Case Examples from the Field.

Missouri medicine·2020
Same author

Sporadic Porphyria Cutanea Tarda as the Initial Manifestation of Hereditary Hemochromatosis.

ACG case reports journal·2020
Same author

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2018
Same author

New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome.

Hepatology communications·2018
Same author

Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

American journal of nephrology·2018
Same author

Hepatitis C.

Postgraduate medicine·2017
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection poses a significant threat for future liver disease and cancer.
  • A new drug regimen offers a powerful tool to combat HCV.
  • Understanding the benefits, risks, and costs of this therapy is crucial for clinicians.

Purpose of the Study:

  • To evaluate the efficacy and safety of peginterferon alfa plus ribavirin for HCV treatment.
  • To identify factors influencing treatment response and optimize patient outcomes.
  • To provide guidance for clinicians on maximizing results and minimizing costs.

Main Methods:

  • Analysis of major clinical trials evaluating 48 weeks of combination therapy.
  • Assessment of sustained virologic response rates.

Related Experiment Videos

  • Identification of patient characteristics and adherence factors associated with higher response rates.

    • Main Results:

    • Sustained virologic responses of 54% and 56% were observed with 48 weeks of therapy.
    • Higher response rates were noted in patients with genotype 2/3, early virologic response, high adherence, and appropriate ribavirin dosing.
    • Common side effects include fatigue, headache, and depression; more serious side effects like neutropenia and anemia may require dose adjustment or discontinuation.

    Conclusions:

    • Peginterferon alfa plus ribavirin is an effective standard therapy for HCV, achieving sustained virologic response in over half of patients.
    • Careful patient selection, thorough education, early response assessment, and proactive side effect management are key to maximizing treatment success and cost-effectiveness.
    • Optimizing adherence and managing side effects can improve outcomes and reduce the need for dose modifications or treatment cessation.